Merck, Inc.
π΅πPhilippines
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Phase 2
Terminated
- Conditions
- Primary Peritoneal Cavity CancerOvarian Cancer
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 132
- Registration Number
- NCT00003880
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: PEGASYS (peginterferon alfa-2a)Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: REBETOL (ribavirin; SCH 18908)Drug: COPEGUS (ribavirin)
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4469
- Registration Number
- NCT00081770
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00081510
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
Phase 3
Completed
- Conditions
- Vomiting
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00080444
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm MetastasisBrain Neoplasms
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00076856
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Phase 2
Completed
- Conditions
- Aspergillosis
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00076869
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2003-12-16
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 512
- Registration Number
- NCT00074529
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
Phase 2
Terminated
- Conditions
- Carcinoma, Squamous CellHead and Neck Neoplasms
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00073450
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00060632
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00060645
- Locations
- πΊπΈ
Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath